SCHEMBL10137041

SCHEMBL10137041

CC[C@H](C)[C@H](NC(C)=O)C(N)=O

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ENPEP Q07075 2/20 0.47
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ALDH1A1 P00352 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.39
PTPN1 P18031 1/20 0.38
HTT P42858 1/20 0.36
CNR2 P34972 1/20 0.36
CA2 P00918 2/20 0.36
CA1 P00915 1/20 0.36
KDM4E B2RXH2 1/20 0.35
MME P08473 1/20 0.35
ACE P12821 1/20 0.35
CPA1 P15085 1/20 0.35
ACE2 Q9BYF1 1/20 0.35
FPR2 P25090 1/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30493819 0.93 ENPEP (0.49) ENPEPMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL23662677 0.89 ENPEP (0.47) ENPEPMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL30493804 0.87 ENPEP (0.48) ENPEPMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL30493610 0.83 MEN1 (0.46) ENPEPMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3703076 0.83 ALDH1A1 (0.48) ENPEPMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL3703074 0.83 ALDH1A1 (0.48) ENPEPMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL3703073 0.83 ALDH1A1 (0.48) ENPEPMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL18771471 0.83 ALDH1A1 (0.47) MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL18771491 0.83 ALDH1A1 (0.47) MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL8354230 0.83 ALDH1A1 (0.47) MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174582-A1 VIPR2 ANTAGONIST PEPTIDE ICHIMARU PHARCOS CO., LTD. (JP) 2023-06-08 US disclosed
EP-4137502-A1 VIPR2 ANTAGONIST PEPTIDE Ichimaru Pharcos Co., Ltd. (JP) 2023-02-22 EP disclosed
WO-2018092723-A1 Ras PROTEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION 学校法人東京理科大学 2018-05-24 WO disclosed
US-20120028888-A1 APJ RECEPTOR COMPOUNDS ANCHOR THERAPEUTICS, INC. 2012-02-02 US disclosed
US-20120028888-A1 APJ RECEPTOR COMPOUNDS ANCHOR THERAPEUTICS, INC. 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028888-A1 APJ RECEPTOR COMPOUNDS APLNR, AP1G1, AP2B1 ENPEP 2893/4885MEN1 4292/4885KMT2A 3381/4885
US-20230174582-A1 VIPR2 ANTAGONIST PEPTIDE VIPR2, NPY2R, NPY5R ENPEP 715/4885MEN1 677/4885KMT2A 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.